[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remimazolam\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remimazolam":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,74,102,137,160,185,209,242,266,289,314,340],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644754","remimazolam-on-the-incidence-of-postoperative-acute-kidney-injury-100644754",false,"NCT07674719","Remimazolam on the Incidence of Postoperative Acute Kidney Injury","The Effect of Intraoperative Remimazolam Administration on the Incidence of Postoperative Acute Kidney Injury After Hepatobiliary and Pancreatic Surgery : a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Ages 19 or older and under 85\n* Patients scheduled to undergo elective hepatopancreatic surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) physical grade 1-3\n* Those who voluntarily consented to a written informed consent form prior to participation in the study\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to other benzodiazepine drugs, including remimazolam, and to the components of this drug (e.g., patients with severe hypersensitivity to dextran 40)\n* Patients with hypersensitivity to propofol\n* Patients with underlying conditions: liver, neurological disorders, or acute narrow-angle glaucoma\n* Patients with severe or acute respiratory failure\n* Patients in shock or a coma\n* Patients taking TCA antidepressants\n* Patients with preoperative chronic kidney disease","ALL","19 Years","85 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"NA","We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.",[27,28,29,30,31,32,33],"Remimazolam","Propofol","Acute Kidney Injury","Hemodynamic Stability","Hepatobiliary Surgery","Fluid Therapy","Fluid Therapy DURING SURGERY","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":21},"2026-06-26",{"date":42,"type":21},"2028-06-26",{"name":44,"class":45},"Seoul National University Bundang Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100644876","phase-4-efficacy-and-safety-of-eleveld-pkpd-model-based-dosing-during-general-anesthesia-100644876","NCT07675850","Efficacy and Safety of Eleveld PK\u002FPD Model-based Dosing During General Anesthesia","Comparison of Efficacy and Safety Between Eleveld PK\u002FPD Model-based Dosing and Standard Dosing During General Anesthesia","Inclusion Criteria:\n\n* Patients aged 19 to 79 years undergoing elective non-cardiac surgery expected to last 60 minutes or longer under general anesthesia with endotracheal intubation\n\nExclusion Criteria:\n\n* Emergency surgery\n* Surgery requiring evoked potential (EP) monitoring\n* Chronic benzodiazepine users\n* Body Mass Index (BMI) ≥ 35 kg\u002F㎡\n* Chronic kidney disease\n* Hepatic dysfunction or chronic liver disease\n* Contraindication or history of hypersensitivity to remimazolam\n* American Society of Anesthesiologists (ASA) physical status ≥ IV\n* Pregnant women\n* Contraindication or history of hypersensitivity to flumazenil","79 Years",{"count":56,"type":21},68,[58],"PHASE4","The goal of this randomized, controlled clinical trial is to evaluate the efficacy, safety, and recovery profile of an individualized, Eleveld pharmacokinetic\u002Fpharmacodynamic model-guided dosing strategy for remimazolam in adult patients undergoing elective non-cardiac surgery under general anesthesia.\n\nThe main questions it aims to answer are:\n\nDoes Eleveld model-guided customized dosing significantly reduce the eye-opening time at the end of surgery compared to standard weight-based dosing?\n\nCan the Eleveld model-guided approach prevent relative drug accumulation and delayed emergence while maintaining an adequate depth of anesthesia and comparable hemodynamic stability?\n\nResearchers will compare the Experimental Group (Eleveld model-guided dosing) to the Control Group (Standard weight-based label dosing) to see if preemptive dose optimization based on individual patient covariates effectively reduces the total drug consumption, frequency of rescue flumazenil administration, and emergence time.\n\nParticipants will:\n\n* Be randomly assigned to receive remimazolam for the induction and maintenance of general anesthesia according to either the Eleveld model-guided customized regimen or the standard weight-based regimen.\n* Have their depth of anesthesia continuously monitored using a Bispectral Index (BIS) sensor.\n* Be assessed for the primary outcome (time to eye-opening upon verbal command after discontinuation of anesthetics) and secondary outcomes, including total drug consumption, hemodynamic stability, and postoperative complications (e.g., re-sedation, delirium, PONV).",[27,61],"Pharmacokinetics and Pharmacodynamics",[27,63,64],"general anesthesia","pharmacokinetics and pharmacodynamics","2026-06-23",{"date":67,"type":38},"2026-06-30",{"date":69,"type":21},"2026-07-30",{"date":71,"type":21},"2027-05-31",{"name":73,"class":45},"Seoul National University Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":4},"100641802","patient-controlled-remimazolam-sedation-under-spinal-anesthesia-100641802","NCT07661810","Patient-controlled Remimazolam Sedation Under Spinal Anesthesia","Patient-controlled Remimazolam Sedation During Primary Hip Arthroplasty Under Spinal Anesthesia: an Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 19 to 70 years with an ASA (American Society of Anesthesiologists) physical status of I or II who are undergoing primary hip arthroplasty under spinal anesthesia.\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patients with contraindications to spinal anesthesia\n* Patients who do not consent to intraoperative sedation\n* Patients with contraindications to remimazolam\n* Patients with a history of allergy or hypersensitivity to remimazolam\n* Patients with a baseline MOAA\u002FS (Modified Observer's Assessment of Alertness\u002FSedation) score of 4 or lower\n* Pregnant women","70 Years",{"count":83,"type":21},104,[24],"The goal of this clinical trial is to compare the efficacy of patient-controlled sedation (PCS) versus clinician-controlled sedation (CCS) using remimazolam in adult patients undergoing primary hip arthroplasty under spinal anesthesia.\n\nThe main questions it aims to answer are:\n\n* Does patient-controlled sedation significantly reduce the total consumption of remimazolam compared to clinician-controlled sedation?\n* Are there differences in secondary outcomes, such as sedation depth , sedation-related adverse events, frequency of airway interventions, and patient\u002Fsurgeon satisfaction?\n\nResearchers will compare the PCS group to the CCS group to see if the patient-controlled method leads to a reduction in total remimazolam consumption while maintaining effective sedation.\n\nParticipants will:\n\n* Be randomly assigned to either the PCS group or the CCS group.\n* In the PCS group: Receive an initial 0.05 mg\u002Fkg remimazolam dose over 1 minute. If deeper sedation is desired, the patient can self-administer a 1 mg bolus of remimazolam via a button press, which has a 1-minute lockout interval.\n* In the CCS group: Receive an initial 0.05 mg\u002Fkg remimazolam dose over 1 minute, followed by a continuous infusion starting at 0.3 mg\u002Fkg\u002Fh. The clinician will assess the MOAA\u002FS score every 10 minutes and adjust the infusion rate to maintain a target MOAA\u002FS score of 3.",[87,88,27,89],"Hip Arthroplasty","Spinal Anesthesia","Patient-controlled Sedation",[91,92,93,94],"patient-controlled sedation","remimazolam","spinal anesthesia","hip arthroplasty","2026-06-16",{"date":97,"type":38},"2026-06-22",{"date":99,"type":21},"2026-07-01",{"date":71,"type":21},{"name":73,"class":45},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":135,"locationsCount":46},"100615253","early-phase-1-remimazolam-neuroimaging-100615253","NCT07290205","Remimazolam NeuroImaging","Neuroimaging of Sedation With Remimazolam","REMAZ","Inclusion Criteria:\n\n* Adults 18-59 years of age, who:\n* have none of the specific exclusion criteria\n* have a valid email address and valid phone number throughout the study\n* free from any non-MRI compatible implants\n\nExclusion Criteria:\n\n* are pregnant or attempting to conceive\n* body mass index (BMI) \\> 35\n* significant memory impairment or hearing loss\n* sleep apnea\n* chronic pain or frequently taking pain medication (including tramadol)\n* chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol)\n* neurologic disease, including seizures and tremor\n* psychiatric diagnoses, including anxiety, depression, panic, or PTSD\n* a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease\n* severe claustrophobia or MRI intolerance\n* have metal implants or non-removable metal piercings\n* having a history of adverse reaction to midazolam (Versed), lorazepam (Ativan) or another benzodiazepine class medication\n* are allergic to dextran\n* daily alcohol or heavy alcohol use; history of alcohol abuse\n* current daily smoker\n* regular or recent marijuana use (including prescribed\u002Fmedical marijuana)\n* illicit drug use, i.e., street drugs\n* regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids",true,"18 Years","59 Years",{"count":114,"type":21},60,[116],"EARLY_PHASE1","This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task",[119,120,27],"Anesthesia","Pain",[27,122,123,124,125,126,127],"functional MRI","electric nerve stimulation","sedation","functional connectivity","memory","pain","RECRUITING","2026-03-27",{"date":131,"type":38},"2026-04-02",{"date":129,"type":38},{"date":134,"type":21},"2027-12-02",{"name":136,"class":45},"Keith M Vogt",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100614306","phase-4-the-effect-of-reversal-of-remimazolam-sedation-with-flumazenil-on-cognitive-function-in-patients-undergoing-hip-arthroplasty-under-spinal-anesthesia-100614306","NCT07277881","The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia","Inclusion Criteria:\n\n* Patient qualified for elective, primary, unilateral, total hip replacement.\n* Patient assessed on the ASA I-III scale.\n* MoCA score obtained during screening ≥ 23 points (to exclude patients with significant pre-existing cognitive impairment).\n* Ability to understand information about the study and express informed, written consent to participate.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to benzodiazepines, flumazenil, local anesthetics\n* Contraindications to spinal anesthesia or patient refusal of this anesthesia technique.\n* Severe liver dysfunction.\n* History of epilepsy or seizures\n* Chronic (daily use for \\> 2 weeks in the last 3 months) use of benzodiazepines or non-benzodiazepine hypnotics (so-called \"Z\" drugs: zolpidem, zopiclone, zaleplon).\n* Alcohol abuse defined as regular consumption of more than: in men: 40 g of pure ethanol at a time; in women: 20 g of pure ethanol at a time, or a history of psychoactive substance dependence.\n* Planned revision hip arthroplasty or bilateral surgery.\n* Significant neurological or psychiatric diseases that may affect the assessment of cognitive function.\n* The need for sedative premedication.",{"count":144,"type":21},150,[58],"This clinical trial aims to establish whether reversing remimazolam sedation with flumazenil can prevent postoperative neurocognitive disorders in patients undergoing total hip replacement surgery. The main questions it aims to answer are:\n\n* Does administering flumazenil after surgery lead to an improvement in cognitive function (measured by the MoCA scale) at 24 hours post-operation compared to a placebo?\n* Does this intervention reduce the incidence of postoperative delirium within the first 48 hours? Researchers will compare flumazenil to a placebo (0.9% saline solution) to see if actively reversing sedation leads to better cognitive outcomes and a lower incidence of delirium.\n\nParticipants will:\n\n* Undergo a planned total hip replacement surgery under spinal anesthesia.\n* Receive sedation with remimazolam during the operation.\n* At the end of the surgery, receive an intravenous injection of the study drug (flumazenil) or a placebo.\n* Undergo assessments for cognitive function (using the MoCA scale) and delirium (using the 4AT scale) before and at multiple time points after the surgery.\n* Complete a questionnaire about their quality of recovery (QoR-15).",[148,149,27,150],"Postoperative Delirium","Sedation","Hip Arthroplasty, Total","2026-01-01",{"date":153,"type":38},"2026-01-06",{"date":155,"type":21},"2026-01",{"date":157,"type":21},"2028-10",{"name":159,"class":45},"Medical University of Gdansk",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100511456","effects-of-flumazenil-on-recovery-after-total-intravenous-anesthesia-with-remimazolam-100511456","NCT05939674","Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam","Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam in Elderly Patients Undergoing Hip Joint Surgery: a Prospective Randomized Controlled Study.","Inclusion Criteria:\n\n* Patients over 65 years old scheduled for hip joint surgery\n\nExclusion Criteria:\n\n* Patients with impaired consciousness or delirium before surgery\n* Patients who are hemodynamically unstable before surgery\n* Patients with a history of neurological or neuromuscular disorders or use of medications that affect neurological or neuromuscular function\n* Patients who have taken sedatives (anti-anxiety medications, antipsychotics, antidepressants, sleep aids) within the past 24 hours\n* Patients with known allergy to benzodiazepine, flumazenil\n* Patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption\n* Patients with hypersensitivity to Dextran40\n* Patients who have been taking benzodiazepine for long term\n* Patients with end stage renal disease requiring hemodialysis\n* Patients with history of acute angle glaucoma\n* Patients with alcohol or substance dependence\n* ASA classification 4 or 5","65 Years",{"count":169,"type":21},24,[24],"Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.",[173,27,174,175],"Flumazenil Adverse Reaction","Hip Joint","Elderly Patients","2025-09-07",{"date":178,"type":38},"2025-09-12",{"date":180,"type":38},"2023-09-19",{"date":182,"type":21},"2026-06",{"name":184,"class":45},"Pusan National University Yangsan Hospital",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":110,"sex":16,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":46},"100596802","application-of-remimazolam-dexmedetomidine-and-esketamine-in-pediatric-preoperative-sedation-100596802","NCT07050212","Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation","A Comparative Study of the Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation","Inclusion Criteria:\n\n1. Children aged 2 to 5 years old\n2. the American Society of Anesthesiologists (ASA) physical status of Class I\n3. scheduled for adenotonsillectomy under general anesthesia, will be included.\n\nExclusion Criteria:\n\n1. Abnormal lung function and respiratory system function\n2. airway obstruction or deformity, history of mental illness\n3. electrocardiogram indicating bradycardia\n4. history of cardiac disease","2 Years","5 Years",{"count":144,"type":21},[24],"By comparing the application effects of three drugs in pediatric preoperative sedation, this study explores the optimal medication regimen, aiming to provide safer, more effective, and more personalized medication options for pediatric preoperative sedation. Additionally, this research will also focus on the impact of these three drugs on postoperative agitation in children, offering valuable references for the overall management of pediatric surgical anesthesia.",[27,198,199],"Dexmedetomidine","Esketamine","2025-07-04",{"date":202,"type":38},"2025-07-10",{"date":204,"type":38},"2025-04-01",{"date":206,"type":21},"2026-03-01",{"name":208,"class":45},"Maternal and Child Health Hospital of Hubei Province",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":227,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100596507","phase-4-remimazolam-and-emergence-delirium-in-pediatrics-100596507","NCT07046364","Remimazolam and Emergence Delirium in Pediatrics","The Effect of Remimazolam on Emergence Delirium in Pediatrics Undergoing Neurosurgery With Sevoflurane Anesthesia","Inclusion Criteria:\n\n* Aged 1 to 6 years old\n* Planned to receive elective neurosurgery under general anesthesia\n* Expected duration of surgery \\> 1 hour\n\nExclusion Criteria:\n\n* Allergy to benzodiazepine\n* Use of other sedatives within 12 hours before surgery such as benzodiazepines, propofol, chloral hydrate, etc.,\n* ASA classification IV or above\n* Unable to complete emergence delirium assessment, such as language, hearing or vision impairment.","1 Year","6 Years",{"count":219,"type":21},248,[58],"Emergence delirium is a common complication in pediatrics undergoing neurosurgery. Previous study showed that a single bolus of remimazolam was associated with lower incidence of postoperative agitation. Present study was designed to investigate if remimazolam supplemented to sevoflurane anesthesia could decrease the risk of emergence delirium in pediatrics undergoing neurosurgery.",[223,224,225,27,226],"Pediatric","Neurosurgery","Sevoflurane Anesthesia","Emergence Delirium",[228,92,229,230,231],"emergence delirium","pediatric","neurosurgery","sevoflurane anesthesia","2025-06-28",{"date":234,"type":38},"2025-07-01",{"date":236,"type":38},"2025-01-01",{"date":238,"type":21},"2027-01-01",{"name":240,"class":45},"Peking University First Hospital",2,{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":46},"100571176","remimazolam-besylate-in-sedation-of-postcardioperative-patients-100571176","NCT06716840","Remimazolam Besylate in Sedation of Postcardioperative Patients","Remimazolam Besylate Versus Propofolfor Sedation of Postcardioperative Patients in Intensive Care Unit: a Prospective,Single-center,Randomized Non-inferior Trial","Inclusion Criteria:\n\n1. age ≥ 18 years ;\n2. admitted to the intensive care unit after cardiac surgery with techanical ventilation；\n3. expected to extubation within 48hours ；\n4. participant has given informed consent\n\nExclusion Criteria:\n\n1. pregnant or lactating women\n2. known or suspected hypersensitivity to the study drug\n3. history of impaired consciousness or psychiatric illness\n4. severe bradycardia with a heart rate of \\\u003C 50 beats per minute\n5. systolic blood pressure \\\u003C 90 mmHg with fluid resuscitation and vasopressor maintenance\n6. atrioventricular block（II or III degree）, Left ventricular ejection fraction(LVEF) \\\u003C30%\n7. participated in other clinical studies within 3 months",{"count":250,"type":21},120,[24],"Intensive care medicine is vital in managing patients after cardiac surgery with endotracheal intubation，in order to provide extensive monitoring to assure clinical stabilization. During this time of recovery, sedation is frequently employed. However, prolonged sedation risks negative sequelae.At present,propofol, benzodiazepines, and dexmedetomidine are typical drugs used for sedation of patients in intensive care unit.Each has its own advantages and disadvantages.The investigators try to find near-ideal agents for sedation,characterized by good sedative effect,minimal adverse effects and rapid awakening facilitating earlier extubation.Remimazolam appeared to be an effective and safe sedative for short term sedation. Study participants were predicated on age (\\> 18 years), admission following cardiac surgery, still mechanical ventilation within 48 hours,and prior informed consent.Participants were randomized to receive remimazolam besylate or propofol in a 1:1 ratio for sedation with a target sedation depth before extubation.Finally，the investigators will compare the sedation effect and safety between the 2 groups ，to prove if remimazolam is appropriate for sedation in patients after cardiac surgery in intensive care unit.",[27,28,149,254,255,256],"Mechanical Ventilation","Intensive Care","Cardiac Surgery","2025-02-16",{"date":259,"type":38},"2025-02-18",{"date":261,"type":38},"2025-02-10",{"date":263,"type":21},"2025-05-31",{"name":265,"class":45},"First Affiliated Hospital of Zhejiang University",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":167,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":46},"100575675","the-effect-of-general-anesthesia-with-remimazolam-and-propofol-on-rhythmic-state-and-cognitive-function-100575675","NCT06775366","The Effect of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function","Effects of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function","Inclusion Criteria:\n\nAge 18-65 years old, ASAI-III class, BMI18.5-25kg\u002Fm2 Inpatients undergoing laparoscopic cholecystectomy The estimated time of operation is 1.5\\~2.5 hours Preoperative brief mental status examination (MMSE) score ≥24 Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\nPregnant or lactating women Patients who are allergic to remimazolam or contraindicated Patients who are dependent on or tolerant to opioids or have long-term alcoholism Serious cardiovascular system, respiratory system, liver and kidney diseases History of obstructive sleep apnea mental disorders or neurological diseases Patients who participated in clinical trials of other drugs within the last 3 months The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study Refuse to participate in the study",{"count":274,"type":21},174,[24],"This study want to observe the effects of remimazolam and propofol for general anesthesia on postoperative rhythm and cognitive function. The observation group was given remimazolam for general anesthesia, and the control group was given propofol for general anesthesia. Both drugs are commonly used as intravenous anesthetics for general anesthesia and have been shown to be safe for use in general anesthesia. The investigators hope can understand the effects of remimazolam and propofol for general anesthesia on rhythm status and cognitive function through this study, further reduce the occurrence of postoperative cognitive function impairment, and enable subjects to better recover.",[278,28,27,279],"Cognitive Functioning","Circadian Rhythm","2025-02-12",{"date":282,"type":38},"2025-02-14",{"date":284,"type":21},"2025-02-24",{"date":286,"type":21},"2026-05-30",{"name":288,"class":45},"The Second Affiliated Hospital of Chongqing Medical University",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":299,"conditions":300,"keywords":303,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":46},"100569781","the-eeg-study-under-remimazolam-anesthesia-in-children-100569781","NCT06698705","The EEG Study Under Remimazolam Anesthesia in Children","Electroencephalogram Study in Children Under Remimazolam Anesthesia - a Prospective,Observational Study","Inclusion Criteria:\n\n1\\. aged 1 years-12 years; 2, with American Society of Anesthesiologists (ASA) physical status I or II; 3, children requiring general anesthesia under remimazolam; 4, parents or legal guardians of children who volunteered to participate in the trial; And signed the informed consent form.\n\nExclusion Criteria:\n\n1. Congenital malformation or other genetic conditions that are thought to affect brain development ;\n2. History of severe heart, brain, liver, kidney and metabolic diseases ;\n3. Premature infants (≤32 weeks);\n4. Upper respiratory tract infection in the last two weeks. -","12 Years",{"count":114,"type":21},"OBSERVATIONAL","The effect of Remimazolam on brain electrical activity. Previous studies have shown that in healthy male volunteers, EEG changes during Remimazolam infusion are characterized by an initial increase in the beta band and a later increase in the delta band. When monitoring the depth of anesthesia, the commonly used Bispectral Index in clinical practice was originally developed for propofol. Therefore, studies have shown that the correlation between the depth of sedation of benzodiazepines such as midazolam and Bispectral Index is weak. In contrast, the beta wave ratio is considered a more suitable EEG indicator for monitoring the sedative effect of Remimazolam. The above indicates that Remimazolam has a specific pattern of influence on EEG activity, especially in the regulation of anesthesia depth, with unique characteristics.",[301,27,302],"Electroencephalography","Child Neglect",[301,27,304],"children","2025-02-04",{"date":307,"type":38},"2025-02-06",{"date":309,"type":38},"2024-11-22",{"date":311,"type":21},"2025-12-01",{"name":313,"class":45},"Second Affiliated Hospital of Wenzhou Medical University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":167,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100556919","phase-1-flumazenil-antagonism-of-remimazolam-in-kidney-transplant-patients-100556919","NCT06531369","Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients","Application of Flumazenil to Antagonize Remimazolam and Evaluation of Remimazolam Plasma Concentration in Kidney Transplant Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and \\\u003C 65 years\n* Patients undergoing elective kidney transplant surgery\n* Signed the informed consent for the clinical study\n\nExclusion Criteria:\n\n* Liver decompensation (Child B\u002FC)\n* History of liver transplant\n* Previous allergies or other serious adverse reactions to narcotic drugs\n* Intraoperative depth monitoring of anesthesia is not expected\n* Preoperative ASA rating of 5\n* Received general anesthesia in the 30 days prior to surgery or plan to receive it again within 30 days\n* Plan to extend airway protection or mechanical ventilation support time after surgery\n* Previous participation in this study",{"count":114,"type":21},[323],"PHASE1","To investigate the effect of different doses of flumazenil antagonism on remimazolam plasma concentration in patients undergoing renal transplantation under general anesthesia.",[326,27,327],"Flumazenil to Antagonize Remimazolam","Renal Transplantation",[329,27,330],"Flumazenil","renal transplantation","2024-07-30",{"date":333,"type":38},"2024-08-01",{"date":335,"type":21},"2024-07",{"date":337,"type":21},"2026-03",{"name":339,"class":45},"Qianfoshan Hospital",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":348,"maxAge":81,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":46},"100507727","remimazolam-for-postoperative-atrial-fibrillation-100507727","NCT05891145","Remimazolam for Postoperative Atrial Fibrillation","The Effect of Remimazolam on Postoperative New-onset Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting","RePAF","Inclusion Criteria:\n\n* 50-70 years old;\n* BMI 18-28 kg\u002Fm2；\n* Selective CABG surgery will be performed at the Yangzhou Institute Heart and Great Vessels, the Affiliated Hospital of Yangzhou University, Yangzhou, China.\n* Patients agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* with any other type of cardiac surgery;\n* pre-operative supraventricular arrhythmia;\n* with moderate or severe valve disease before surgery;\n* with a history of chemotherapy or radiotherapy;\n* with a history of thoracic or cardiovascular surgery;\n* diuretics usage before the surgery.","50 Years",{"count":350,"type":21},50,[24],"Atrial fibrillation (AF) is the most common cardiac severe arrhythmia globally and is associated with an increased risk of mortality and morbidity, with a loss of 6.0 million disability-adjusted life-years worldwide in 2017, conferring 0.24% of total disability-adjusted life-years globally. Due to the absence of knowledge of AF pathogenesis, currently, available therapies do not prevent AF onset or progression in 85% of patients. Despite the identification of novel druggable targets that are involved in the pathogenesis of AF, the translation of these findings to clinical drug studies is limited.\n\nPostoperative atrial fibrillation (POAF) is the most common type of secondary AF. The incidence of POAF after coronary artery bypass grafting (CABG) is approximately 30%. About 16% of patients developed POAF in cardiac surgery even with the international guideline recommended perioperative beta-blocker intervention.\n\nRemimazolam is a newly approved benzodiazepine sedative indicated for the induction and maintenance of procedural sedation in adults, with significantly reduced sedation and recovery time. It was also found to be with an anti-inflammatory effect and therefore might have an impact on POAF since AF is closely related to the inflammatory response of myocardial tissue and inflammatory factors such as TNF-α. So, the RePAF trial intends to explore whether remimazolam application in induction and maintenance for general anesthesia during cardiac surgery can reduce the incidence of POAF in patients with CABG, and the effect on the postoperative plasma levels of inflammatory factors and stress factors.",[354,27],"Coronary Artery Bypass Grafting",[27,356,357,358,359,360,361,362,363,119,364],"CABG","Postoperative atrial fibrillation","Postoperative new-onset atrial fibrillation","Coronary artery disease","CAD","Coronary artery bypass graft","Myocardial infarction","Revascularization","Ischemic heart disease","2023-06-05",{"date":367,"type":38},"2023-06-06",{"date":369,"type":38},"2023-02-01",{"date":371,"type":21},"2026-12",{"name":373,"class":45},"Yangzhou University"]